Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seretide for FEV1 Decline in Post-HSCT Children
NCT04655508Phase 3Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of salmeterol + fluticasone in Bronchiolitis Obliterans Syndrome (BOS), sponsored by Assistance publique - Hôpitaux de Paris. Started May 2021; status: terminated.
02
Drugs
salmeterol + fluticasone
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on NCT04655508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655508.